Isotretinoin does not prevent basal cell carcinoma

Robinson, J. K.

doi:10.1001/archderm.128.7.975

Cited by 7 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Isotretinoin was reported previously to be effective in the chemoprevention and chemotherapy of BCCs in patients with multiple BCG (Majewski et al, 1994;Peck et al, 1988Peck et al, ,1992Peck, 1987), but recently chemoprevention of BCCs by retinoids was questioned (Robinson and Salasche, 1992). Basal cell carcinoma is the most common malignant tumor of the skin (reviewed in Miller, 1991a).…”

Section: Introductionmentioning

confidence: 99%

Expression of retinoic acid receptor proteins in basal cell carcinomas: an immunohistochemical analysis.

Kamradt

Reichrath²

1996

J Histochem Cytochem.

View full text Add to dashboard Cite

We analyzed immunohistochemically the expression of RAR proteins in basal cell carcinomas (BCCs; n = 15) in situ. The labeling pattern for the different types of RARs was compared with the staining pattern of the proliferation marker Ki-67 in the same tumors. We found strong immunoreactivity for RAR-alpha and moderate immunoreactivity for RAR-gamma in all BCCs analyzed, whereas no or very weak staining for RAR-beta protein was detected. In contrast to RAR-gamma, which revealed no or only marginal differences in staining intensities, RAR-alpha immunoreactivity was consistently stronger in BCCs compared to adjacent unaffected epidermis. In general, labeling of BCCs for RAR-alpha and RAR-gamma was pronounced in cells of the palisade and peripheral cells, whereas staining in the center of the tumors was heterogeneous. Eleven of the 15 BCCs analyzed revealed no visual correlation in comparing labeling patterns for RAR-alpha and RAR-gamma with the labeling pattern for Ki-67. In four specimens, expression of RAR-alpha, RAR-gamma, and Ki-67 proteins was confined to peripheral tumor cells. Our findings indicate that (a) RAR-alpha and RAR-gamma proteins are, in contrast to RAR-beta, strongly expressed in BCCs; (b) expression of RAR-alpha is upregulated in BCCs compared to keratinocytes of uninvolved epidermis; and (c) BCCs may be targets for potentially preventive or therapeutic treatment with RAR-alpha- or RAR-gamma-selective retinoic acid metabolites.

show abstract

Section: Introductionmentioning

confidence: 99%

Expression of retinoic acid receptor proteins in basal cell carcinomas: an immunohistochemical analysis.

Kamradt

Reichrath²

1996

J Histochem Cytochem.

View full text Add to dashboard Cite

show abstract

“…2), should be removed immediately to avoid progression to SCC with the capability of metastasis. The efficacy of synthetic retinoids (acitretin, isotretinoin) and beta-carotin in prevention of malignant epithelial tumors in immunodeficient patients is controversial [24,25]. Neither oral isotretinoin nor beta-carotin seem to be able to prevent basal cell carcinomas in high-risk patients with chronic actinic skin damage [25].…”

Section: Yearmentioning

confidence: 99%

“…The efficacy of synthetic retinoids (acitretin, isotretinoin) and beta-carotin in prevention of malignant epithelial tumors in immunodeficient patients is controversial [24,25]. Neither oral isotretinoin nor beta-carotin seem to be able to prevent basal cell carcinomas in high-risk patients with chronic actinic skin damage [25]. In addition, hyperostosis, which is a well-known side effect of long-term retinoid treatment (high doses over at least 3 years), might occur in patients with immunodeficiency after low daily (0.14 mg/kg/day) or cumulative doses.…”

Section: Yearmentioning

confidence: 99%